Sector News

Boehringer to acquire NBE-Therapeutics for $1.43bn

December 13, 2020
Life sciences

Boehringer Ingelheim has signed a binding agreement to acquire all shares of clinical-stage Swiss biotechnology company NBE-Therapeutics for a total of €1.18bn ($1.43bn) to enhance its cancer pipeline portfolio.

The deal also includes contingent clinical and regulatory milestones.

NBE-Therapeutics develops antibody-drug conjugates (ADC) and advances targeted cancer therapies obtained from its immune-stimulatory iADC platform.

The acquisition will give Boehringer access to an innovative platform that will be used to build an ADC portfolio, as well as develop potential combinations with assets from its cancer immunology portfolio.

NBE-Therapeutics lead compound and an anti-ROR1 ADC, NBE-002 is currently in Phase I clinical trials for triple-negative breast cancer and other solid tumours.

Boehringer Ingelheim Board of Managing Directors member Michel Pairet said: “NBE-Therapeutics’ iADC platform adds exceptional tumour targeting capabilities to our oncology portfolio.

“Together with our immune cell-targeting assets, this could enable new powerful combinations that will allow for efficacious and durable treatments for patients.”

This deal will enhance Boehringer’s focus on targeted cancer cell-directed therapies and adds to current capabilities in antigen discovery and antibody and T-cell engager technologies.

With the acquisition, NBE-Therapeutics will work as a new site within Boehringer’s R&D network from its campus in Basel.

NBE-Therapeutics CEO Bertrand Damour said: “We look forward to progressing NBE-002, our lead programme and best-in-class anti-ROR1 ADC, and to continuing the fight against cancer alongside Boehringer Ingelheim with its strong clinical development capabilities.”

The closing of the deal, subject to customary closing conditions, is anticipated in the first quarter of next year.

Boehringer also signed an agreement to acquire all the shares of German biotech company Labor Dr Merk & Kollegen to strengthen its cancer immunology programme.

by Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend